Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy - Neuropsychiatrie- Recherche épidémiologique et clinique (U1061) Access content directly
Journal Articles Nature and Science of Sleep Year : 2022

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Abstract

Lower-sodium oxybate (LXB) is an oxybate medication approved to treat cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy 7 years of age and older in the United States. LXB was developed as an alternative to sodium oxybate (SXB), because the incidence of cardiovascular comorbidities is higher in patients with narcolepsy and there is an elevated cardiovascular risk associated with high sodium consumption. LXB has a unique formulation of calcium, magnesium, potassium, and sodium ions, containing 92% less sodium than SXB. Whereas the active oxybate moiety is the same for LXB and SXB, their pharmacokinetic profiles are not bioequivalent; therefore, a phase 3 trial in participants with narcolepsy was conducted for LXB. This review summarizes the background on oxybate as a therapeutic agent and its potential mechanism of action on the gamma-aminobutyric acid type B (GABAB) receptor at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons. The rationale leading to the development of LXB as a lower-sodium alternative to SXB and the key efficacy and safety data supporting its approval for both adult and pediatric patients with narcolepsy are also discussed. LXB was approved in August 2021 in the United States for the treatment of idiopathic hypersomnia in adults. Potential future developments in the field of oxybate medications may include novel formulations and expanded indications for other diseases.
Fichier principal
Vignette du fichier
nss-14-531.pdf (1.26 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
licence : CC BY NC - Attribution - NonCommercial

Dates and versions

hal-04530633 , version 1 (03-04-2024)

Licence

Attribution - NonCommercial

Identifiers

Cite

Yves Dauvilliers, Richard K Bogan, Karel Šonka, Markku Partinen, Nancy Foldvary-Schaefer, et al.. Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. Nature and Science of Sleep, 2022, Volume 14, pp.531-546. ⟨10.2147/nss.s279345⟩. ⟨hal-04530633⟩
0 View
2 Download

Altmetric

Share

Gmail Facebook X LinkedIn More